Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Interleukin-2 (IL-2) shows promise in treating metastatic cancer but is limited by severe toxicities.
• Tumor necrosis factor (TNF) plays a key role in IL-2-induced toxicity and may also influence its anti-tumor effects.

Purpose of the Study:

• To investigate if pentoxifylline (PTXF), a TNF inhibitor, can reduce IL-2 toxicity without compromising its anti-cancer efficacy.
• To evaluate the therapeutic index of IL-2 when combined with PTXF.

Main Methods:

• Female C57BL/6 mice with fibrosarcoma pulmonary metastases were treated with IL-2, IL-2 plus PTXF, PTXF alone, or saline.
• Effects on TNF production, organ infiltration, edema, liver function, and blood cell counts were assessed.
• Tumor response was measured by quantifying pulmonary metastases 21 days after therapy cessation.

Main Results:

• PTXF significantly suppressed IL-2-induced TNF production, organ lymphocytic infiltration, edema, hepatic dysfunction, leukopenia, and thrombocytopenia.
• The combination therapy with PTXF preserved the anti-tumor efficacy of IL-2.
• Morbidity and mortality associated with IL-2 treatment were reduced by PTXF.

Conclusions:

• Pentoxifylline effectively ameliorates IL-2-induced toxicities.
• Combining PTXF with IL-2 enhances the therapeutic index for cancer treatment.
• PTXF is a promising agent for improving the clinical utility of IL-2 in oncology.